News Releases

October 2020

October 13, 2020 10/13/2020 Takeda Accelerates Digital Transformation with Accenture and AWS

October 12, 2020 10/12/2020 Safety and Efficacy of Subcutaneous Entyvio® (Vedolizumab) Sustained During Long-term Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis

October 8, 2020 10/8/2020 First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine

September 2020

September 24, 2020 9/24/2020 Announcement of decision on a basic plan for a merger (simple merger/short-form merger) with a wholly owned subsidiary

September 18, 2020 9/18/2020 Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress

September 16, 2020 9/16/2020 Takeda to Divest TachoSil® to Corza Health for €350 Million

September 15, 2020 9/15/2020 Takeda Opens New R&D Cell Therapy Manufacturing Facility to Support Expansion of Next-Generation Clinical Programs

September 9, 2020 9/9/2020 Takeda Announces Results from Phase 3 Clinical Trial Evaluating NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma

September 8, 2020 9/8/2020 Takeda Divests Select Non-Core Assets in Europe to Cheplapharm for Approximately $562 million USD